Please login to the form below

Not currently logged in
Email:
Password:

PI3K

This page shows the latest PI3K news and features for those working in and with pharma, biotech and healthcare.

Chi-Med cues up two more regulatory filings in cancer

Chi-Med cues up two more regulatory filings in cancer

Following after its first three drugs are potential first-in-class selective Syk inhibitor HMPL-523, in phase 1 testing for non-Hodgkin’s lymphoma, and a PI3K delta inhibitor

Latest news

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    development and commercialisation. 45. Infinity Pharmaceuticals/ Verastem. Duvelisib, oral inhibitor of PI3K‐delta and PI3K‐gamma for haematological cancers (p3).

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    970. Infinity / AbbVie. Licence and collaboration. IPI-145 an oral PI3K-delta, gamma inhibitor in Phase III for chronic lymphocytic leukaemia .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...